Recent

% | $
Quotes you view appear here for quick access.

Swisher Hygiene Inc. Message Board

jlwbigd 16 posts  |  Last Activity: Aug 28, 2015 7:24 AM Member since: Mar 25, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • jlwbigd by jlwbigd Aug 28, 2015 7:24 AM Flag

    Should we not see an update on financing today or next week?

    Sentiment: Buy

  • jlwbigd jlwbigd Aug 26, 2015 10:51 AM Flag

    Assuming DF moves forward with favorable terms (why would they not?) and that announcement is made where do you see the PPS? DF does not want nor need to have a fire sale for Angel??

    Sentiment: Buy

  • jlwbigd jlwbigd Aug 26, 2015 9:20 AM Flag

    No kidding..the days of blowing smoke up DF's skirt are gone..this is a very good message from DT. GLTA

    Sentiment: Buy

  • Reply to

    Roth Capital

    by jlwbigd Aug 13, 2015 11:32 AM
    jlwbigd jlwbigd Aug 18, 2015 3:04 PM Flag

    I expect Roth to raise the PPS estimate . by 9-1?? Just a guess. I just felt bad when we dropped thru .52. I expect .43 again this week??? I am long until SOC for sure in November.

    Sentiment: Buy

  • Reply to

    Plausible scenarios

    by chitownstockpicker Aug 17, 2015 12:52 PM
    jlwbigd jlwbigd Aug 17, 2015 1:19 PM Flag

    Listening to the CC on Friday Dean did not sound like a guy that didn't have a plan in his pocket. He did. What ever deal is going to be done is going to happen before 9-1.

    Sentiment: Buy

  • jlwbigd by jlwbigd Aug 13, 2015 11:32 AM Flag

    ImmunoCellular (IMUC) SPA from FDA 'Significant', Roth Capital Says
    10:53 AM ET, 08/13/2015 - StreetInsider
    Roth Capital analyst Joseph Pantginis reiterated a Buy rating and $3 price target on ImmunoCellular Therapeutics (NYSE: IMUC) after the company announced the receipt of a Special Protocol Assessment (SPA) from the FDA for the pending start of the ICT-107 study in front-line glioblastoma. "We believe this is a significant achievement for IMUC, which has been quite engaged with the regulatory authorities following the Phase II data showing the survival benefit in HLA-A2 patients," Pantginis said. For an analyst ratings summary and ratings history on ImmunoCellular Therapeutics click here. For more ratings news on ImmunoCellular Therapeutics click here. Shares of ImmunoCellular Therapeutics closed at $0.44 yesterday.

    Sentiment: Buy

  • Hmm..I think the scientific supports speaks volumes about the perceived potential here..as Mr Market watches. GLTA.

    Sentiment: Buy

  • Reply to

    I would not get too excited

    by johnamkins Aug 13, 2015 9:02 AM
    jlwbigd jlwbigd Aug 13, 2015 9:07 AM Flag

    John, according to the published short interest is 1%

    Sentiment: Buy

  • Reply to

    Somebody Is Seeing Opportunity

    by upsman25out Aug 10, 2015 12:38 AM
    jlwbigd jlwbigd Aug 11, 2015 1:22 PM Flag

    I don't think its a fail at all. Strong dollar will have anyone and everyone who exports goods looking to make up the loss on currency..only way is by cutting cos Fight the trend is no bueno.

    Sentiment: Buy

  • Reply to

    Newly Diagnosed GBM

    by cdaniel394 Jul 13, 2015 2:53 PM
    jlwbigd jlwbigd Jul 13, 2015 4:04 PM Flag

    Blessings.

    Sentiment: Buy

  • jlwbigd jlwbigd Jul 12, 2015 11:44 AM Flag

    John after the raise earlier this year and as of 3-31-15 the company had 34,M cash with no debt. There is no cash raise pending today..unless someone wants to collaborate or buyin..as Jane said. I am a mind reader in my spare time. My opinion is that management felt that the raise this year was limited to continuing day to day with a healthy start on P3. Lets say they took a measured approach. I feel certain that the next raise will be on better terms for them and for the stockholders. My hot sports opinion. The update on P2 will tell all this fall. GLTA.

    Sentiment: Buy

  • Reply to

    Thoughts

    by rajavaranasi Jul 9, 2015 8:23 PM
    jlwbigd jlwbigd Jul 10, 2015 8:13 AM Flag

    Your info regarding $ for running P3 is incorrect. 3-31-15 Cash on hand 34,000,000. No debt. What do you think that 34M is for? Sell your $10.00 and go away.

    Sentiment: Buy

  • Reply to

    Ready to go to the moon!

    by turnoffmindcontroltv Jul 6, 2015 10:29 PM
    jlwbigd jlwbigd Jul 7, 2015 8:59 AM Flag

    You must have a writer for this comedy .. funny..your killing it!

    Sentiment: Buy

  • Reply to

    No reverse split this year.

    by gustudentmd Jul 2, 2015 5:07 PM
    jlwbigd jlwbigd Jul 4, 2015 7:59 AM Flag

    Ok..I can't find the article but it was a spin off of the Celgene/Juno partnership talking about the technology. Here is an article from street Insider from Nov 2014 about the Caltech agreement with IMUC. Needless to say if this tech sector finds favor as a viable technology then IMUC is a steal. GLTA..

    Roth Capital affirms ImmunoCellular Therapeutics (AMEX: IMUC) at Buy with a price target of $3 following news that the company has licensed from the California Institute of Technology (Caltech) the exclusive rights to a novel technology to develop antigen specific killer T cells.

    Analyst Joseph Pantginis commented, We believe this new initiative by IMUC into a new immunotherapy modality is a promising one as it expands its profile and capabilities to use the immune system to attach the tumor. The main advantage of the new licensed technology over other engineered T cell approaches such as chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies is the duration of their effects. CAR and TCR technologies are currently limited by the limited immune responses they elicit. Since this new technology uses stem cells, it has the potential to have a lasting immune activation as the pool of stem cells will supplement the depletion in the differentiated engineered T cells. Additionally, with this new T cell-based approach, IMUC could potentially combine their approaches. i.e., use of its dendritic cell technology that activates the immune system with antigen-specific T cells that target and destroy tumor cells. This sits in line with the company's stated goals of introducing new immunotherapy technologies that can expand and complement its current platform. We now look forward to updated survival data from the ICT-107 Phase II at SNO in November as well as the start of the Phase III following positive FDA feedback.

    Sentiment: Buy

  • Reply to

    No reverse split this year.

    by gustudentmd Jul 2, 2015 5:07 PM
    jlwbigd jlwbigd Jul 4, 2015 7:42 AM Flag

    Catalyst pending..signing a patient registration deal with a couple of agencies that farm for patients, updated data from P2 in Oct or Nov. Intiation of P3 trial The biggest being the continued data improvement from P2..Plus there is always the possibility someone partners up. GLTA..there was an an article published yesterday pointing to this same technology as the next big thing in cancer treatment. I can't find it now..will look somemore.

    Sentiment: Buy

  • Reply to

    When IMUC files Chapter 11 what will happen?

    by golf.paul123 Jun 1, 2015 4:47 PM
    jlwbigd jlwbigd Jun 1, 2015 6:10 PM Flag

    You go away when it files chapter 11. Thats what happens.

    Sentiment: Hold

SWSH
1.2126+0.0826(+7.31%)2:19 PMEDT